C
C. Schmidt
Researcher at International AIDS Vaccine Initiative
Publications - 29
Citations - 1642
C. Schmidt is an academic researcher from International AIDS Vaccine Initiative. The author has contributed to research in topics: Immunogenicity & Virus. The author has an hindex of 16, co-authored 29 publications receiving 1563 citations.
Papers
More filters
Journal ArticleDOI
Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes
Nilu Goonetilleke,Stephen Moore,Len Dally,Nicola Winstone,Inese Cebere,Abdul Mahmoud,Susana Pinheiro,Geraldine M. Gillespie,Denise Brown,Vanessa Loach,Joanna Roberts,Ana Guimarães-Walker,Peter Hayes,Kelley Loughran,Carole Smith,Jan De Bont,Carl Verlinde,Danii Vooijs,C. Schmidt,Mark Boaz,Jill Gilmour,Pat Fast,Lucy Dorrell,Tomáš Hanke,Andrew J. McMichael +24 more
TL;DR: The data demonstrate that prime-boost vaccination with recombinant DNA and MVA vectors can induce multifunctional HIV-1-specific T cells in the majority of vaccinees.
Journal ArticleDOI
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Matilu Mwau,Inese Cebere,Julian Sutton,Priscilla Chikoti,Nicola Winstone,Edmund G.-T. Wee,Tara S Beattie,Yun-Hsiang Chen,Lucy Dorrell,Helen McShane,C. Schmidt,Mary Brooks,Sandip Patel,Joanna Roberts,Christopher P. Conlon,Sarah Rowland-Jones,Job J. Bwayo,Andrew J. McMichael,Tomáš Hanke +18 more
TL;DR: Both the DNA and the MVA vaccines alone and in a DNA prime-MVA boost combination were safe and induced HIV-specific responses in 14 out of 18, seven out of eight and eight out of nine volunteers, respectively, which are very encouraging and justify further vaccine development.
Journal ArticleDOI
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
Sandhya Vasan,Arlene Hurley,Arlene Hurley,Sarah J. Schlesinger,Sarah J. Schlesinger,Drew Hannaman,David F. Gardiner,Daniel Dugin,Mar Boente-Carrera,Roselle Vittorino,Marina Caskey,Johanne Andersen,Yaoxing Huang,Josephine H. Cox,Tony Tarragona-Fiol,Dilbinder K. Gill,Hannah Cheeseman,Lorna Clark,Len Dally,Carol Smith,C. Schmidt,Harriet Park,Jakub Kopycinski,Jill Gilmour,Patricia E. Fast,Robert M. Bernard,David D. Ho,David D. Ho +27 more
TL;DR: This is the first demonstration in healthy volunteers that EP is safe, tolerable, and effective in improving the magnitude, breadth and durability of cellular immune responses to a DNA vaccine candidate.
Journal ArticleDOI
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine
Enoch Muyanja,Aloysius Ssemaganda,Pearline Ngauv,Rafael Cubas,Helene Perrin,Divya Srinivasan,Glenda Canderan,Benton Lawson,Jakub Kopycinski,Amanda S. Graham,Dawne K. Rowe,Michaela J. Smith,Denis Gaucher,Sharon Isern,Scott F. Michael,Guido Silvestri,Thomas H. Vanderford,Erika Castro,Giuseppe Pantaleo,Joel Singer,Jill Gillmour,Noah Kiwanuka,Noah Kiwanuka,Annet Nanvubya,C. Schmidt,Josephine Birungi,Josephine H. Cox,Elias K. Haddad,Pontiano Kaleebu,Pontiano Kaleebu,Patricia E. Fast,Rafick Pierre Sekaly,Lydie Trautmann +32 more
TL;DR: It is demonstrated that an activated immune microenvironment prior to vaccination impedes efficacy of the YF-17D vaccine in an African cohort and suggest that vaccine regimens may need to be boosted in African populations to achieve efficient immunity.
Journal ArticleDOI
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Inese Cebere,Lucy Dorrell,Helen McShane,Alison Simmons,Sheena McCormack,C. Schmidt,Carol Smith,Mary Brooks,Joanna Roberts,Simon C Darwin,Patricia E. Fast,Christopher P. Conlon,Sarah Rowland-Jones,Andrew J. McMichael,Tomáš Hanke +14 more
TL;DR: The results from these initial small phase I trials administering the pTHr.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies.